Tests endocannabinoid-acting drugs on bladder muscle tissue from bladder cancer surgery
Studies bladder muscle tissue from adults with bladder cancer, in the laboratory, using endocannabinoid-acting drugs.
Plain-language title generated from the registry record
Registry title: Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle
Key facts
- Where
- Rome, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with bladder cancer who are planned for bladder removal surgery. A small sample of healthy-looking bladder tissue is taken from the removed bladder for lab tests.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Bladder cancer at any stage, planned for surgery meant to remove the disease (upfront surgery, or surgery after more than 6 weeks of treatment before the operation).
- Earlier treatment
- Patients who had treatment before surgery must have had it for more than 6 weeks. Patients treated with radio-chemotherapy cannot have surgery less than 6 weeks afterwards.
Main reasons for not taking part
- Under 18 years old
- Urgent or emergency surgery
- Corticosteroid treatment for immune-related rheumatic diseases
- Radio-chemotherapy with surgery less than 6 weeks later
- Refusing to sign the written consent
Read by machine on 12 November 2026.
Where in Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo A. Gemelli, 100168 - RomaRome, ItalyContact: Maria Chiara Sighinolfi, Dr.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Trial code
- NCT07545694
- Record updated
- 22 April 2026
- Original description
The goal of this observational, in vitro study is to evaluate the effects of drugs that modulate the endocannabinoid system on spontaneous and neuronally induced contractility of the human detrusor. The study will include adult patients undergoing elective radical cystectomy for bladder cancer. The main questions it aims to answer are whether modulation of endocannabinoid receptors, enzymes involved in endocannabinoid synthesis and degradation, and endocannabinoid transport mechanisms alters basal detrusor contractility and modifies excitatory motor responses induced by neuronal activation.Read full original descriptionShow less
Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle
The goal of this observational, in vitro study is to evaluate the effects of drugs that modulate the endocannabinoid system on spontaneous and neuronally induced contractility of the human detrusor. The study will include adult patients undergoing elective radical cystectomy for bladder cancer. The main questions it aims to answer are whether modulation of endocannabinoid receptors, enzymes involved in endocannabinoid synthesis and degradation, and endocannabinoid transport mechanisms alters basal detrusor contractility and modifies excitatory motor responses induced by neuronal activation.
Participants undergoing radical cystectomy will provide written informed consent for the collection of a small sample of macroscopically healthy bladder tissue from the surgical specimen. Detrusor muscle strips will be prepared and studied in vitro using organ bath techniques. Contractile activity will be recorded under baseline conditions and after electrical field stimulation, as well as following exposure to pharmacological modulators of the endocannabinoid system. Demographic, clinical, and pathological data will also be collected for descriptive analysis.
Inclusion: Age ≥ 18 years; Patients with bladder carcinoma at any stage of disease, undergoing upfront surgery or neoadjuvant therapy for more than 6 weeks, scheduled for surgery with curative/demolitive intent; Signed written informed consent to participate in the study.
Exclusion: Patients treated with corticosteroid therapy for immunorheumatic diseases; Patients treated with radio-chemotherapy and undergoing surgery less than 6 weeks prior; Age < 18 years; Procedures performed on an urgent/emergency basis; Refusal to sign written informed consent to participate in the study.